CN118613284A - 用于口服给予的组合物和方法 - Google Patents

用于口服给予的组合物和方法 Download PDF

Info

Publication number
CN118613284A
CN118613284A CN202280074852.8A CN202280074852A CN118613284A CN 118613284 A CN118613284 A CN 118613284A CN 202280074852 A CN202280074852 A CN 202280074852A CN 118613284 A CN118613284 A CN 118613284A
Authority
CN
China
Prior art keywords
polypeptide
polypeptide construct
seq
amino acid
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280074852.8A
Other languages
English (en)
Chinese (zh)
Inventor
恩戈克·泰
乔纳森·波莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imagination Pharmaceutical Co ltd
Original Assignee
Imagination Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagination Pharmaceutical Co ltd filed Critical Imagination Pharmaceutical Co ltd
Publication of CN118613284A publication Critical patent/CN118613284A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
CN202280074852.8A 2021-12-11 2022-12-09 用于口服给予的组合物和方法 Pending CN118613284A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288579P 2021-12-11 2021-12-11
US63/288,579 2021-12-11
PCT/US2022/081277 WO2023108126A1 (en) 2021-12-11 2022-12-09 Compositions and methods for oral administration

Publications (1)

Publication Number Publication Date
CN118613284A true CN118613284A (zh) 2024-09-06

Family

ID=86731317

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280074852.8A Pending CN118613284A (zh) 2021-12-11 2022-12-09 用于口服给予的组合物和方法

Country Status (11)

Country Link
US (1) US20250388638A1 (https=)
EP (1) EP4444352A4 (https=)
JP (1) JP2024545981A (https=)
KR (1) KR20240141165A (https=)
CN (1) CN118613284A (https=)
AU (1) AU2022405604A1 (https=)
CA (1) CA3235948A1 (https=)
IL (1) IL312382A (https=)
MX (1) MX2024007105A (https=)
WO (1) WO2023108126A1 (https=)
ZA (1) ZA202404443B (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
KR100944034B1 (ko) * 2007-04-19 2010-02-24 한올제약주식회사 프로테아제-내성 폴리펩티드의 경구 투여 제형
KR102497242B1 (ko) * 2016-11-13 2023-02-09 이매진 파마 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법
PL3746111T3 (pl) * 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową

Also Published As

Publication number Publication date
WO2023108126A9 (en) 2023-08-24
CA3235948A1 (en) 2023-06-15
MX2024007105A (es) 2024-06-24
EP4444352A4 (en) 2025-12-17
KR20240141165A (ko) 2024-09-25
WO2023108126A1 (en) 2023-06-15
AU2022405604A2 (en) 2024-07-11
IL312382A (en) 2024-06-01
JP2024545981A (ja) 2024-12-17
ZA202404443B (en) 2025-10-29
US20250388638A1 (en) 2025-12-25
AU2022405604A1 (en) 2024-06-13
EP4444352A1 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
CN101389650B (zh) 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
US20180112193A1 (en) Csf1 therapeutics
US20140364362A1 (en) Therapeutic agents comprising insulin amino acid sequences
CA2806399A1 (en) Recombinantly expressed insulin polypeptides and uses thereof
EP4013395A1 (en) Compositions and particles for payload delivery
JP2012515221A (ja) 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤
EP3442562B1 (en) An il-22 dimer for use in treating necrotizing enterocolitis
Lee et al. Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity
US20210038697A1 (en) Virus-like nanocapsid for oral delivery of insulin
KR20230039594A (ko) 경구 펩티드 투여
CN118613284A (zh) 用于口服给予的组合物和方法
CA2571542C (en) Aequorin-containing compositions and methods of using same
HK40109249A (zh) 用於口服给予的组合物和方法
US12404307B2 (en) Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
CN101959532A (zh) 经鼻给药用药物组合物
US20250242032A1 (en) Aggregate formed by means of assembling chalcogen heterocyclic compound and insulin, and preparation method therefor, and insulin oral preparation
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
TW202535451A (zh) 經修飾之調酸素及其使用方法
Zhang et al. Exendin-4 and Its Derivatives for Diabetes and Obesity: Old Story and New Hope
HK40002973A (en) An il-22 dimer for use in treating necrotizing enterocolitis
HK40002973B (en) An il-22 dimer for use in treating necrotizing enterocolitis
JPWO2023108126A5 (https=)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109249

Country of ref document: HK